Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 19.91
(1.01%)
CNY 19.91
(1.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 136.97 Million CNY | 13.58% |
| 2022 | 120.59 Million CNY | 52.8% |
| 2021 | 78.92 Million CNY | -41.0% |
| 2020 | 133.76 Million CNY | -32.15% |
| 2019 | 197.15 Million CNY | 48.29% |
| 2018 | 132.95 Million CNY | 95.57% |
| 2017 | 67.98 Million CNY | -14.42% |
| 2016 | 79.43 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 7.4 Million CNY | -74.09% |
| 2024 Q1 | 28.58 Million CNY | -24.26% |
| 2024 Q3 | 11.96 Million CNY | 61.51% |
| 2023 Q4 | 37.74 Million CNY | 10.14% |
| 2023 FY | 136.97 Million CNY | 13.58% |
| 2023 Q3 | 34.27 Million CNY | -10.39% |
| 2023 Q2 | 38.24 Million CNY | 43.23% |
| 2023 Q1 | 26.7 Million CNY | -47.47% |
| 2022 FY | 120.59 Million CNY | 52.8% |
| 2022 Q3 | 20.95 Million CNY | 1.29% |
| 2022 Q2 | 20.69 Million CNY | -26.39% |
| 2022 Q1 | 28.11 Million CNY | 59.31% |
| 2022 Q4 | 50.83 Million CNY | 142.53% |
| 2021 Q2 | 37.69 Million CNY | 23.0% |
| 2021 Q1 | 30.64 Million CNY | 339.59% |
| 2021 FY | 78.92 Million CNY | -41.0% |
| 2021 Q4 | 17.64 Million CNY | 349.95% |
| 2021 Q3 | -7.05 Million CNY | -118.73% |
| 2020 FY | 133.76 Million CNY | -32.15% |
| 2020 Q4 | 6.97 Million CNY | -70.15% |
| 2020 Q3 | 23.35 Million CNY | -74.99% |
| 2020 Q2 | 93.38 Million CNY | 829.13% |
| 2020 Q1 | 10.05 Million CNY | -76.78% |
| 2019 Q4 | 43.27 Million CNY | -19.97% |
| 2019 Q3 | 54.07 Million CNY | 0.0% |
| 2019 FY | 197.15 Million CNY | 48.29% |
| 2018 FY | 132.95 Million CNY | 95.57% |
| 2017 FY | 67.98 Million CNY | -14.42% |
| 2016 FY | 79.43 Million CNY | 0.0% |